All In Biotech

Drug Trial Radar · NCT03842969

An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies

An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Intrathecally Administered RO7234292 (RG6042) in Patients With Huntington's Disease

Last checked: Nov 19, 2026Latest source record: Aug 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 236 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

236

Actual

Start

Apr 23, 2019

Primary completion

Mar 25, 2022

Study completion Mar 30, 2022

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Feb 15, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the long-term safety and tolerability of RO7234292 (RG6042) in participants who have completed other F. Hoffmann-La Roche, Ltd.-sponsored and/or Genentech-sponsored studies in the Huntington's disease (HD) in the development program for RG6042.

Conditions

  • Huntington Disease

Interventions

  • RO7234292 (RG6042)Drug

    Intrathecal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Treatment Emergent Adverse EventsTime frame: Up to Approximately 3 Years
  2. Number of Participants With Suicidal Ideation, Suicidal Behavior, and Self-Injurious Behavior Without Suicidal Intent Based on the Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: Up to approximately 3 Years
  3. Change From Baseline in Cognition, Using Montreal Cognitive Assessment (MoCA)Time frame: Up to Approximately 3 Years

Locations

38 sites in 8 countries. Site status is shown where the registry gives one.

  • Uab Medicine

    Birmingham, Alabama

  • University of California San Diego

    La Jolla, California

  • Stanford Univ Medical Center

    Palo Alto, California

  • SC3 Research Group, Inc

    Pasadena, California

  • CenExel Rocky Mountain Clinical Research, LLC

    Englewood, Colorado

  • Georgetown University; Research Division, Psychiatry

    Washington D.C., District of Columbia

  • University of South Florida

    Tampa, Florida

  • Northwestern University

    Chicago, Illinois

  • John Hopkins University School of Medicine

    Baltimore, Maryland

  • Dent Neurological Institute

    Amherst, New York

  • Columbia University

    New York, New York

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • The University of Texas Health Science Center at Houston; McGovern Medical School

    Houston, Texas

  • Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck; Department fuer Neurologie

    Innsbruck, Austria

  • University of British Columbia Hospital; Division of Neurology

    Vancouver, British Columbia, Canada

  • Centre for Movement Disorders

    North YORK, Ontario, Canada

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, Canada

  • Centre Hospitalier de l?Université de Montréal (CHUM)

    Montreal, Quebec, Canada

  • Charité - Universitätsmed. Berlin, Klinik für Psychiatrie und Psychotherapie; Abt. Neuropsychiatrie

    Berlin, Germany

  • St. Josef-Hospital, Neurologische Klinik der Ruhr-Uni; Huntington-Center NRW, Abt. Neurodegeneration

    Bochum, Germany

  • Universitätsklinikum Ulm; Klinik für Neurologie

    Ulm, Germany

  • IRCCS Casa Sollievo Della Sofferenza; Unità Ricerca e Cura Huntington e Malattie Rare

    San Giovanni Rotondo (FG), Apulia, Italy

  • Fondazione IRCCS Istituto Neurologico Carlo Besta; U.O.C. Genetica Medica-Neurogenetica

    Milan, Lombardy, Italy

  • Universitair Medisch Centrum Groningen

    Groningen, Netherlands

  • LUMC

    Leiden, Netherlands

  • Hospital Universitario de Badajoz; Servicio de Neurología

    Badajoz, Spain

  • Hospital Clinic Servicio de Neurologia

    Barcelona, Spain

  • Hospital de la Santa Creu i Sant Pau; Servicio de Neurologia

    Barcelona, Spain

  • Hospital Universitario de Burgos. Servicio de Neurología

    Burgos, Spain

  • Hospital Ramon y Cajal; Servicio de Neurologia

    Madrid, Spain

  • Fundacion Jimenez Diaz; Servicio de Neurología

    Madrid, Spain

  • Hospital Universitario Virgen Macarena; Servicio de Neurologia

    Seville, Spain

  • Birmingham and Solihull Mental Health Foundation Trust; Institute of Clinical Sciences

    Birmingham, United Kingdom

  • Cambridge Centre for Brain Repair; Department of Clinical Nuerosciences, Addenbrookes Hospital

    Cambridge, United Kingdom

  • University Hospital of Wales; Division of Psychological Medicine and Clinical Neurosciences

    Cardiff, United Kingdom

  • University College London Hospitals NHS Foundation Trust - University College Hospital

    London, United Kingdom

  • Central Manchester University Hospitals NHS Foundation Trust; Manchester Centre for Genomic Medicine

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.